A comparison of screening methods for sleep disorders in Australian community pharmacies: A randomized controlled trial

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Fuller, Joanne M ^a   Wong, Keith K ^a,b   Grunstein, Ronald ^a,b   Krass, Ines ^a   Patel, Jayshree ^a   Saini, Bandana ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PHARMACY; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; RISK ASSESSMENT ONLY PROTOCOL; RISK ASSESSMENT PLUS OBJECTIVE MARKER OF POSSIBLE UNDERLYING OBSTRUCTIVE SLEEP APNEA; RISK FACTOR; SCREENING TEST; SLEEP DISORDER; SLEEP DISORDERED BREATHING; COMPARATIVE STUDY; DEMOGRAPHY; MASS SCREENING; MIDDLE AGED; PATIENT REFERRAL; POLYSOMNOGRAPHY; PROCEDURES; SLEEP DISORDERS;

AUSTRALIA; DEMOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PHARMACIES; POLYSOMNOGRAPHY; REFERRAL AND CONSULTATION; RISK FACTORS; SLEEP DISORDERS;

EID: 84903579400     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101003     Document Type: Article

References (37)

1. Committee on Sleep Medicine and Research (2006) Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington: Institute of Medicine.
2. Deloitte Access Economics (2011) Re-awakening Australia. The economic cost of sleep disorders in Australia, 2010. Sleep Health Foundation
3. Dikeos D, Georgantopoulos G (2011) Medical comorbidity of sleep disorders. Curr Opin Psych 24:346-354.
4. Skaer TL, Sclar DA (2010) Economic implications of sleep disorders. Pharmacoeconomics 28(11):1015-1023.
5. Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, et al. (2010) Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 122:352-360.
6. Young T, Finn L, Peppard PE, Szklo-Coxe M, Austin D, et al. (2008) Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 31:1071-1078.
7. Marshall NS, Wong KK, Liu PY, Cullen SRJ, Knuiman MW, et al. (2008) Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 31:1079-1085.
8. Laugsand LE, Vatten LJ, Platou C, Janszky I (2011) Insomnia and the Risk of Acute Myocardial Infarction: A Population Study. Circulation 124:2073-2081.
9. AlGhanim N, Comondore VR, Fleetham J, Marra CA, Ayas NT (2008) The Economic Impact of Obstructive Sleep Apnea. Lung 186:7-12.
10. Chai-Coetzer CL, Antic NA, Rowland LS, Catcheside PG, Esterman A, et al. (2011) A simplified model of screening questionnaire and home monitoring for obshructive sleep apnoea in primary care. Thorax 66:213-219.
11. Bartlett DJ, Marshall NS, Williams A, Grunstein RR (2008) Predictors of primary medical care consultation for sleep disorders. Sleep Med 9:857-864.
12. Australian Government Department of Health and Ageing: Primary Health Care Reform in Australia - Report to support Australia's First National Primary Health Care Strategy. Element 3: More focussed on preventive care, including support of healthy lifestyles. Available: www.yourhealth.gov.au. Accessed 2011 December 15.
13. Baraitser P, Pearce V, Holmes J, Horne N, Boynton PM (2007) Chlamydia testing in community pharmacies: evaluation of a feasibility pilot in south east London. Qual Saf Health Care 16:303-307.
14. Krass I, Mitchell B, Clarke P, Brillant M, Dienaar R, et al. (2007) Pharmacy diabetes care program: Analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. Diabetes Res Clin Pract 75:339-347.
15. Mangum SA, Kraenow KR, Narducci WA (2003) Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm 43:50-55.
16. Hersberger KE, Renggli VP, Nirkko AC, Mathis J, Schwegler K, et al. (2006) Screening for sleep disorders in community pharmacies - evaluation of a c campaign in Switzerland. J Clin Pharm Ther 31:35-41.
17. Tran A, Fuller JM, Wong KK, Krass I, Grunstein R, et al. (2009) The devleopment of a sleep disorder screening program in Australian community pharmacies. Pharm World Sci 31:473-480.
18. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14:540-545.
19. Bastein CH, Vallieres A, Morin CM (2001) Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2:297-307.
20. Maislin G, Pack AI, Kribbs NB, Smith PL, Schwartz AR, et al. (1995) A survey screen for prediction of sleep apnea. Sleep 18:158-166.
21. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, et al. (2003) Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4:101-119.
22. Sharwood LN, Elkington J, Stevenson M, Grunstein RR, Meuleners L, et al. (2012) Assessing sleepiness and sleep disorders in Australian long-distance commercial vehicle drivers: self-report versus an "at home" monitoring device. Sleep 35:469-475.
23. Rofail LM, Wong KKH, Unger G, Marks GB, Grunstein RR (2009) The utility of single nasal airflow pressure transducer in the diagnosis of OSA at home. Sleep 33:1097-1105.
24. Crockett JA, Taylor SJ, McLeod LJ (2008) Patient responses to an integrated service, initiated by community pharmacists, for the prevention of osteoporosis. Int J Pharm Pract 16:65-72.
25. Effective Health Care Program, Comparative Effectiveness Review Number 32 (2011) Diagnosis and treatment of obstructive sleep apnea in adults, 2011. Agency for Healthcare Research and Quality, Dept of Health & Human Services, USA.
26. Bland JM (2000) Sample size in guidelines trials. Fam Pract 17:S17-S20.
27. R Development Core Team (2011) R: A language and environment for statitical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3- 900051-07-0. Available: http://www.R-project.org/.
28. The Pharmacy Guild of Australia (2009) Guild Digest.
29. Hanes CA, Wong KK, Saini B (2014) Clinical services for obstructive sleep apnea patients in pharmacies: the Australian experience. Int J Clin Pharm. [Epub ahead of print] PubMed PMID: 24562977.
30. Maiman LA, Hildreth NG, Cox C, Greenland P (1992) Improving referral compliance after public cholesterol screening. Am J Public Health 82:804-809.
31. Snella KA, Canales AE, Irons BK, Sleeper-Irons RB, Villarreal MC, et al. (2006) Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc 46:370-377.
32. Verne JE, Aubrey R, Love SB, Talbot IC, Northover JMA (1998) Population based randomized study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing. BMJ 317:182-185.
33. Allen H, Diamandis S, Saini B, Marshall D, Gavagna G, et al. A Collaborative Screening, Referral and Management Process to Improve Health Outcomes in Chronic Obstructive Pulmonary Disease (COPD) report no. IIG052, The Pharmacy Guild of Australia, Canberra. Available: www.pharmacyguild.org.au. Accessed online 2012 August 23.
34. Australian Institute of Health and Welfare, Australia's Health 2008. (2008) Canberra Australia.
35. Alattar M, Harrington JJ, Mitchell MM, Sloane P (2007) Sleep Problems in Primary Care: A North Carolina Family Practice Research Network (NC-FPRN) Study. J Am Board Fam Med 20:365-374.
36. Marin JM, Carrizo SJ, Vincente E, Agusti AGN (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365:1046-1053.
37. George CF (2001) Reduction in motor vehicle collisions following treatment of sleep apnoea with a nasal CPAP. Thorax 56:508-512.